Alderley Park, UK & Shenzhen, China – April 28th 2025 – ImmunoKey Ltd., a UK-based biotechnology company pioneering next-generation CAR-T therapies for solid tumours, today announced a strategic collaboration with OxTium, a leading China-based artificial intelligence (AI) for bioscience company. This partnership will harness OxTium’s capabilities to enhance the safety and efficacy of CAR-T therapies for cancer patients worldwide.

CAR T-cell therapy, a revolutionary approach in cancer treatment, has demonstrated remarkable success in hematologic malignancies. However, its application in solid tumours presents significant challenges, including tumour heterogeneity and immune evasion. By integrating ImmunoKey’s expertise in cellular therapies with OxTium’s cutting-edge in silico analytics, the collaboration aims to develop novel strategies to optimise ImmunoKey’s CARKey™ platform technology.

“We are excited to partner with OxTium to explore how AI and bioinformatics can unlock the full potential of CAR-T therapies for solid tumours,” said Dr. John Bridgeman, CSO of ImmunoKey Ltd. “This collaboration represents an exciting step towards developing safe and effective treatments for patients with solid cancers.”

Dr. Jin, CEO of OxTium, said “Partnering with ImmunoKey allows us to bring our biological foundational model expertise to the forefront of oncology innovation, ultimately benefiting patients who need more effective treatment options.”

The collaboration underscores a growing synergy between biotechnology and AI, paving the way for groundbreaking advancements in cancer immunotherapy.

About ImmunoKey
ImmunoKey Ltd. is a UK-based biotechnology company developing next-generation CAR T-cell therapies to overcome the challenges of treating solid tumours. The company’s proprietary CARKey™ platform enables multi-antigen targeting while minimising off-tumour toxicity, supported by complementary technologies AmpliT™ and ReviT™ to enhance T-cell persistence and function in the tumour microenvironment. Backed by a leadership team with proven success in cell therapy development and clinical translation, ImmunoKey is advancing a pipeline of novel immunotherapies to address critical unmet needs in oncology.

For media inquiries, please contact:

ImmunoKey Ltd.: Dr. John Bridgeman
Email: info@immunokey.co.uk
Website: https://www.immunokey.co.uk

OxTium Co., Ltd.: Dr. Yongcheng Jin
Email: yongcheng.jin@oxtium.com
Website: https://www.oxtium.com/